RBC Capital cuts Intra-Cellular stock rating, hikes target to $132
RBC Capital Markets adjusted its stance on Intra-Cellular Therapies shares, downgrading the biopharmaceutical company from Outperform to Sector Perform. The firm, however, raised its price target on ...
RBC Capital cuts CF Industries stock rating amid valuation concerns
RBC Capital Markets adjusted its stance on CF Industries Holdings Inc. (NYSE:CF), downgrading the stock from 'Outperform' to ...
CF Industries downgraded at RBC Capital on valuation
Financial-services firm RBC downgraded CF Industries from Outperform to Sector Perform, citing fair valuation and potential ...
RBC Capital Keeps Their Hold Rating on Headwater Exploration (CDDRF)
RBC Capital analyst Michael Harvey maintained a Hold rating on Headwater Exploration (CDDRF – Research Report) yesterday and set a price target ...